Linc AB (LINC) - Total Liabilities
Based on the latest financial reports, Linc AB (LINC) has total liabilities worth Skr11.62 Million SEK (≈ $1.25 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Linc AB generate cash to assess how effectively this company generates cash.
Linc AB - Total Liabilities Trend (2018–2025)
This chart illustrates how Linc AB's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Linc AB's assets to evaluate the company's liquid asset resilience ratio.
Linc AB Competitors by Total Liabilities
The table below lists competitors of Linc AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liaoning He Eye Hospital Group Co. LTD.
SHE:301103
|
China | CN¥331.80 Million |
|
Dalian Thermal Power Co Ltd
SHG:600719
|
China | CN¥2.19 Billion |
|
Zinzino AB Series B
ST:ZZ-B
|
Sweden | Skr1.02 Billion |
|
Daewon Cable Co. Ltd. Preference Shares
KO:006345
|
Korea | ₩174.33 Billion |
|
Oron Group Investments & Holdings Ltd
TA:ORON
|
Israel | ILA1.81 Billion |
|
Ion Beam Applications SA
BR:IBAB
|
Belgium | €508.01 Million |
|
Yaxing Chem
SHG:600319
|
China | CN¥2.33 Billion |
|
Importadora y Exportadora de la Patagonia SA
BA:PATA
|
Argentina | AR$528.04 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Linc AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LINC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Linc AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Linc AB (2018–2025)
The table below shows the annual total liabilities of Linc AB from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr11.62 Million ≈ $1.25 Million |
+32.69% |
| 2024-12-31 | Skr8.76 Million ≈ $942.39K |
+200.31% |
| 2023-12-31 | Skr2.92 Million ≈ $313.81K |
+2.42% |
| 2022-12-31 | Skr2.85 Million ≈ $306.38K |
-97.82% |
| 2021-12-31 | Skr130.48 Million ≈ $14.04 Million |
-9.49% |
| 2020-12-31 | Skr144.17 Million ≈ $15.51 Million |
+2731.78% |
| 2019-12-31 | Skr5.09 Million ≈ $547.87K |
+143.82% |
| 2018-12-31 | Skr2.09 Million ≈ $224.70K |
-- |
About Linc AB
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and o… Read more